Related Experiment Videos
Tacrolimus clearance is age-dependent within the pediatric population.
D Przepiorka1, D Blamble, S Hilsenbeck
1Baylor College of Medicine Center for Cell and Gene Therapy, Houston, Texas 77030, USA.
Bone Marrow Transplantation
|October 21, 2000
Summary
Pediatric hematopoietic stem cell transplant patients require careful tacrolimus monitoring. Younger children (<6 years) exhibit higher drug clearance, necessitating dose adjustments to maintain therapeutic levels and prevent subtherapeutic dosing.
Area of Science:
- Pharmacology
- Pediatric Hematology
- Immunosuppression
Background:
- Graft-versus-host disease (GVHD) prevention is critical post-hematopoietic stem cell transplantation (HSCT).
- Tacrolimus is a key immunosuppressant, with established adult dosing guidelines.
- Pediatric tacrolimus dosing efficacy and reproducibility remain less understood.
Purpose of the Study:
- To evaluate the achievement of target whole blood tacrolimus concentrations in children undergoing HSCT using the standard adult initial dose.
- To analyze tacrolimus pharmacokinetics, including clearance, in pediatric HSCT recipients across different age groups.
- To assess the safety and efficacy of tacrolimus dosing in children post-HSCT.
Main Methods:
- Retrospective review of 55 pediatric HSCT patients (6 months to 18 years).
- Analysis of tacrolimus blood levels and calculation of drug clearance during intravenous and oral administration.
- Comparison of tacrolimus levels and clearance across pediatric age strata.
Main Results:
- 71% of children achieved target tacrolimus levels (5-15 ng/ml) initially with intravenous dosing.
- 87% were within the safe range (5-20 ng/ml), with 9% toxic and 4% subtherapeutic levels.
- Younger children (<6 years) demonstrated significantly higher weight-normalized tacrolimus clearance compared to older children and adults.
Conclusions:
- The standard initial intravenous dose of tacrolimus may not consistently achieve therapeutic concentrations in all pediatric HSCT patients.
- Younger children (<6 years) exhibit higher tacrolimus clearance, requiring closer monitoring and potential dose adjustments.
- Therapeutic drug monitoring is crucial in the initial peritransplant period, especially for young children, to optimize immunosuppression and prevent GVHD.